Stock Events

Stock Events

Gemini Therapeutics 

$19.89
22
+$18.54+1,367.9% Friday 21:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.77
-1.48
-1.18
-0.89
Expected EPS
-1.645008
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
0Revenue
-71.87MNet Income

Analyst Ratings

$101.00Average Price Target
The highest estimate is 125.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GMTX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Disc Medicine's treatments for blood disorders.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, including blood disorders, potentially competing with Disc Medicine.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a broad portfolio including treatments for HIV, liver diseases, and hematology, directly competing with Disc Medicine's focus.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for blood disorders, making it a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals develops medicines for serious medical conditions, including hematologic conditions, competing with Disc Medicine.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a wide range of healthcare solutions, including treatments for blood disorders, directly competing with Disc Medicine.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which involve hematologic disorders, making it a competitor.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genomic medicines, including gene-edited cell therapies for blood disorders, competing with Disc Medicine.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is pioneering RNA interference (RNAi) therapeutics, which could target similar diseases as Disc Medicine.

About

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Employees
24
Country
US
ISIN
US36870G1058

Listings

XNAS
US
IRON
BOATS
BOATS
IRON.BOATS

0 Comments

Share your thoughts

FAQ

What is Gemini Therapeutics stock price today?▼
The current price of GMTX is $19.89 USD — it has increased by +1,367.9% in the past 24 hours. Watch Gemini Therapeutics stock price performance more closely on the chart.
What is Gemini Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gemini Therapeutics stocks are traded under the ticker GMTX.
What is Gemini Therapeutics revenue for the last year?▼
Gemini Therapeutics revenue for the last year amounts to 0 USD.
What is Gemini Therapeutics net income for the last year?▼
GMTX net income for the last year is -71.87M USD.
How many employees does Gemini Therapeutics have?▼
As of April 02, 2026, the company has 24 employees.
In which sector is Gemini Therapeutics located?▼
Gemini Therapeutics operates in the Manufacturing sector.
When did Gemini Therapeutics complete a stock split?▼
Gemini Therapeutics has not had any recent stock splits.